Amakem's rock inhibitor rolling towards the market
This article was originally published in Scrip
Belgian biotech company Amakem has begun a proof-of-concept study with its lead product, the rho kinase (ROCK) inhibitor AMA0076, in glaucoma and ocular hypertension, after raising €18 million last year in a series A financing. The product is designed to avoid the risk of systemic and local side-effects such as hyperaemia that have caused problems for other products in this class, and uses the company's Localized Drug Action platform.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.